Testing effectiveness (Phase 2)Looking for participantsNCT06441747
What this trial is testing
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Who this might be right for
Cholangiocarcinoma
Australasian Gastro-Intestinal Trials Group 40